DNA Vaccine Potential
Inovio has created a novel platform for developing and delivering “universal” DNA-based vaccines against diseases such as influenza, HIV, malaria, dengue, and cervical cancer. Inovio’s universal vaccines have shown preclinical results indicating their potential to protect against new, unknown strains of an infectious disease such as the currently circulating H1N1 “swine flu.”
Dr. J. Joseph [...]
Broad U.S. Patent Issued for Vaxfectin(R)-Formulated DNA Vaccines for Influenza
Vical Incorporated receives U.S. Patent No. 7,582,613 covering Vaxfectin(R)-formulated DNA vaccines for influenza. The patent provides broad coverage for any circulating or potential influenza viruses, including both seasonal and pandemic strains.
The company is currently developing Vaxfectin(R)-formulated DNA vaccines for both H5N1 avian-origin and H1N1 swine-origin pandemic influenza. Both vaccines are formulated with the company’s [...]
Flu Vaccine Produces Robust Immune Responses
New vaccine of Vical Incorporated against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. Vical [...]
DNA Vaccines against Swine Influenza A (H1N1) in Evaluation
Inovio Biomedical Corporation in collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania is evaluating DNA vaccine candidates against swine influenza A (H1N1) virus. These vaccines, delivered using Inovio’s proprietary electroporation technology, have the potential to provide protection against a broad scope of existing as well [...]
Protein Sciences Corporation Announced Production of H1N1 Swine Flu Vaccine
Protein Sciences Corporation (PSC) announced that it commenced manufacturing of a vaccine to protect humans against the H1N1 “swine flu” virus. The Company estimates that it can produce 100,000 doses this week and at least 100,000 doses per week thereafter. The vaccine, called PanBlok®, is made using PSC’s proprietary baculovirus and insect cell manufacturing technology. [...]
DNA Vaccine Platform: Reaching Milestones of $6 Million NIH Grant
Vical Incorporated has successfully completed second-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine manufacturing process with the potential to produce several million doses of vaccines in a matter of days.
The RapidResponse(tm) system is designed to allow extremely rapid and large-scale production of [...]
Antibody-Based HIV Vaccine: New Approaches
According to John R. Mascola, M.D., deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine. Attempts to create a vaccine that induces antibodies that prevent HIV [...]
DoD Explores New DNA Vaccine Delivery Method
Connie Schmaljohn, senior research scientist at the U.S. Army Medical Research Institute of Infectious Diseases, announced that DoD scientists are exploring a new DNA vaccine delivery method at the webcast “Armed with Science: Research and Applications for the Modern Military”.
“DNA offers a number of advantages over conventional vaccine approaches, especially with regard to biodefense vaccines. [...]
